Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 6 , Pages 456-464 , November 2010

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

  • Karin Yurko-Mauro

      Affiliations

    • Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    • Corresponding Author InformationCorresponding author. Tel.: 443-542-2524; Fax: 410-997-7789.
    • ,
  • Deanna McCarthy

      Affiliations

    • Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    • ,
  • Dror Rom

      Affiliations

    • Prosoft Software, Inc, Wayne, PA, USA
    • ,
  • Edward B. Nelson

      Affiliations

    • Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    • ,
  • Alan S. Ryan

      Affiliations

    • Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    • ,
  • Andrew Blackwell

      Affiliations

    • Cambridge Cognition Ltd, Cambridge United Kingdom
    • ,
  • Norman Salem Jr.

      Affiliations

    • Clinical Research Department, Martek Biosciences Corporation, Columbia, MD, USA
    • ,
  • Mary Stedman

      Affiliations

    • Stedman Clinical Trials, Tampa, FL, USA
    • ,
  • on behalf of the MIDAS Investigators

References 

  1. Alzheimer's Association. Alzheimer's disease and maintaining brain and memory health national survey results, 2004. Available at http://www.alz.org/alzheimers_disease_publications_reports.asp. Accessed February 15, 2005.
  2. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148:427–434
  3. Heude B, Ducimetiere P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA study. Am J Clin Nutr. 2003;77:803–808
  4. Beydoun MA, Kaufman JS, Satia JA, Rosamond W, Folsom AR. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: the Atherosclerosis Risk in Communities Study. Am J Clin Nutr. 2007;85:1103–1111
  5. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids. 2000;35:1305–1312
  6. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol. 2006;63:1545–1550
  7. Noel K, Hoffman J, Ellis L, Yurko-Mauro K, Cella C, Sercus B, et al. DHA and cognitive function in the elderly: a systematic review of the literature. Res Pract Alzheimer's Dis. 2006;11:381–387
  8. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60:940–946
  9. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62:275–280
  10. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res. 2001;40:1–94
  11. Salem N, Litman B, Kim H-Y, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001;36:945–959
  12. Martin DS, Spencer P, Horrobin DF, Lynch MA. Long-term potentiation in aged rats is restored when the age-related decrease in polyunsaturated fatty acid concentration is reversed. Prostaglandins Leukot Essent Fatty Acids. 2002;67:121–130
  13. Tsukada H, Kakiuchi T, Fukumoto D, Nishiyama S, Koga K. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys. Brain Res. 2000;862:180–186
  14. Petursdottir AL, Farr SA, Morley JE, Banks WA, Skuladottir GV. Effect of dietary n-3 polyunsaturated fatty acids on brain lipid fatty acid composition, learning ability, and memory of senescence-accelerated mouse. J Gerontol A Biol Sci Med Sci. 2008;63:1153–1160
  15. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci. 2005;25:3032–3040
  16. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007;27:4385–4395
  17. van de Rest O, Geleijnse JM, Kok FJ, van Staveren WA, Dullemeijer C, Olderikkert MG, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology. 2008;71:430–438
  18. Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1538–1544
  19. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006;63:1402–1408
  20. Wild K, Howieson D, Webbe F, Seelye A, Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimer's Dement. 2008;4:428–437
  21. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia. 1994;5:266–281
  22. de Jager CA, Milwain E, Budge M. Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests. Psychol Med. 2002;32:483–491
  23. Cargin JW, Maruff P, Collie A, Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. Brain Cogn. 2006;60:146–155
  24. Small SA, Tsai WY, DeLaPaz R, Mayeux R, Stern Y. Imaging hippocampal function across the human life span: is memory decline normal or not?. Ann Neurol. 2002;51:290–295
  25. Egerhazi A, Berecz R, Bartok E, Degrell I. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:746–751
  26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th ed). Washington, DC: American Psychiatric Association; 1994;
  27. Crook T, Bartus R, Ferris SH, Whitehouse PJ, Cohen GD, Gerston S. Age associated memory impairment: proposed diagnostic criteria. Dev Neuropsychol. 1986;2:261–276
  28. Benisek D, Bailey-Hall E, Oken H, Masayesva S, Arterburn L. Validation of a simple food frequency questionnaire as an indicator of long chain omega-3 intake. In: Inform 2002; Abstracts of the 93rd Annual AOCS Meeting and Expo; 2002; Montreal, Quebec, Canada:S96.
  29. Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83:1467S–76S
  30. Ryan AS, Keske MA, Hoffman JP, Nelson EB. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors. Am J Ther. 2009;16:183–192
  31. FDA. Agency Response Letter Gras Notification No. GRN000137; February 12 2004.
  32. Zelinski EM, Gilewski MJ. A 10-item Rasch modeled memory self-efficacy scale. Aging Ment Health. 2004;8:293–306
  33. Galasko D, Bennett DA, Sano M, Marson D, Kaye J, Edland SD. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20:S152–S169
  34. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  35. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37–49
  36. Arterburn LM, Oken HA, Hoffman JP, Bailey-Hall E, Chung G, Rom D, et al. Bioequivalence of docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food. Lipids. 2007;42:1011–1024
  37. USDA. Nutrient intakes from food: mean amounts consumed per individual, one day, 2003-2004. USDA, Agricultural Research Service, 2007. Available at http://www.ars.usda.gov/ba/bhnrc/fsrg. Accessed December 17, 2007
  38. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart Disease and Stroke Statistics—2009 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181
  39. Fowler KS, Saling MM, Conway EL, Semple JM, Louis WJ. Paired associate performance in the early detection of DAT. J Int Neuropsychol Soc. 2002;8:58–71
  40. Blackwell AD, Sahakian BJ, Vesey R, Semple JM, Robbins TW, Hodges JR. Detecting dementia: novel neuropsychological markers of preclinical Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:42–48
  41. Swainson R, Hodges JR, Galton CJ, Semple J, Michael A, Dunn BD, et al. Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord. 2001;12:265–280
  42. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med. 2006;260:211–223
  43. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension. 1999;34:253–260

 Conflicts of Interest Disclosure: With the exception of Drs. Dror Rom, Andrew Blackwell, and Mary Stedman, the other authors are employed by Martek Biosciences Corporation. Dr. Rom and Dr. Blackwell were consultants to the study. The participating clinical investigators are listed as a group in the acknowledgement section of the manuscript.

 Contributors: Blackwell, Nelson, Rom, Yurko-Mauro contributed to the study concept and design. Blackwell, McCarthy, Nelson, Rom, Yurko-Mauro and Stedman participated in study conduct and collection of the data. Rom had responsibility for the statistical analysis. Blackwell, Nelson, Rom, Ryan, Salem, Yurko-Mauro contributed to the interpretation of data. Blackwell, Ryan, Yurko-Mauro contributed to the drafting of the manuscript and McCarthy, Nelson, Rom, Ryan, Salem, Stedman and Yurko-Mauro participated in the revision of the manuscript. The corresponding author had full access to all data in the study after study unblinding, and had final responsibility for the writing of the report and the decision to submit for publication. The study was funded by Martek Biosciences Corporation.

PII: S1552-5260(10)00040-3

doi: 10.1016/j.jalz.2010.01.013

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 6 , Pages 456-464 , November 2010

Article Tools

* Image Usage & Resolution